# Clinical Cases: COPD and Asthma

## Case 1: COPD Exacerbation

### Patient Presentation
A 67-year-old man with a 50-pack-year smoking history and known COPD (GOLD Stage III) presents with 3 days of worsening shortness of breath, increased sputum production, and change in sputum color from white to yellow-green. He has been using his rescue inhaler every 2 hours with minimal relief. His home medications include tiotropium, fluticasone-salmeterol, and albuterol PRN.

### Vital Signs
- Blood Pressure: 148/88 mmHg
- Heart Rate: 104 bpm
- Respiratory Rate: 26/min
- Oxygen Saturation: 86% on room air
- Temperature: 37.9°C

### Physical Examination
- General: Moderate respiratory distress, using accessory muscles, speaking in phrases
- HEENT: Pursed lip breathing
- Cardiovascular: Tachycardic, distant heart sounds
- Pulmonary: Decreased breath sounds bilaterally, diffuse expiratory wheezes, prolonged expiratory phase, barrel chest
- Extremities: No edema, no cyanosis

### Initial Workup
- **ABG (room air)**: pH 7.32, PaCO2 58 mmHg, PaO2 52 mmHg, HCO3 28 mEq/L
- **CBC**: WBC 13,200/μL with 78% neutrophils
- **BMP**: Normal
- **Chest X-ray**: Hyperinflation, flattened diaphragms, no infiltrates
- **Procalcitonin**: 0.18 ng/mL

### Clinical Image
![COPD Chest X-ray](image_01.png)
*Figure 1: Chest X-ray demonstrating hyperinflation with flattened hemidiaphragms and increased AP diameter characteristic of COPD.*

**Image Source**: Educational illustration for teaching purposes.

### Questions

1. **What is the Anthonisen classification of this COPD exacerbation?**
   - A) Type I (all three cardinal symptoms)
   - B) Type II (two of three cardinal symptoms)
   - C) Type III (one cardinal symptom)
   - D) Not classifiable

2. **What do the ABG results indicate?**
   - A) Uncompensated respiratory acidosis
   - B) Compensated respiratory acidosis (acute on chronic hypercapnic respiratory failure)
   - C) Metabolic acidosis
   - D) Respiratory alkalosis

3. **What is the target oxygen saturation in this patient?**
   - A) 95-100%
   - B) 88-92%
   - C) 80-85%
   - D) >97%

4. **Outline the management of acute COPD exacerbation.**

5. **When is non-invasive positive pressure ventilation (NIPPV) indicated?**

### Answers

1. **A) Type I (all three cardinal symptoms)** - The Anthonisen criteria include: (1) increased dyspnea, (2) increased sputum volume, (3) increased sputum purulence. Type I has all three; this patient meets all criteria.

2. **B) Compensated respiratory acidosis (acute on chronic hypercapnic respiratory failure)** - The elevated HCO3 (28) indicates metabolic compensation for chronic hypercapnia. The acute acidemia (pH 7.32) suggests acute-on-chronic respiratory failure with superimposed acute hypercapnia.

3. **B) 88-92%** - In COPD patients with chronic hypercapnia, the target SpO2 is 88-92%. Higher oxygen levels can suppress hypoxic ventilatory drive and worsen hypercapnia and respiratory acidosis.

4. **Management of acute COPD exacerbation**:
   - **Bronchodilators**: SABA (albuterol) ± SAMA (ipratropium) via nebulizer
   - **Corticosteroids**: Prednisone 40 mg daily for 5 days (or IV methylprednisolone)
   - **Antibiotics**: If purulent sputum or requiring ventilation (azithromycin, doxycycline, or fluoroquinolone)
   - **Oxygen**: Target SpO2 88-92% via controlled oxygen (Venturi mask)
   - **NIPPV**: If respiratory acidosis persists (pH <7.35, PaCO2 >45) despite initial treatment
   - **VTE prophylaxis**: Pharmacologic prophylaxis unless contraindicated

5. **Indications for NIPPV in COPD exacerbation**:
   - Respiratory acidosis (pH <7.35, PaCO2 >45 mmHg)
   - Severe dyspnea with accessory muscle use
   - Persistent hypoxemia despite supplemental oxygen
   - Contraindications include: decreased consciousness (unable to protect airway), hemodynamic instability, facial trauma, copious secretions, recent GI surgery

---

## Case 2: Acute Severe Asthma

### Patient Presentation
A 24-year-old woman with a history of asthma since childhood presents with severe shortness of breath that started 6 hours ago after exposure to her friend's cat. She has used her albuterol inhaler approximately 15 times today with minimal relief. She has been hospitalized for asthma twice in the past year, including one ICU admission requiring intubation.

### Vital Signs
- Blood Pressure: 135/82 mmHg
- Heart Rate: 124 bpm
- Respiratory Rate: 32/min
- Oxygen Saturation: 89% on room air
- Temperature: 37.0°C
- Peak flow: Unable to perform

### Physical Examination
- General: Severe respiratory distress, sitting upright, unable to speak full sentences
- HEENT: Diaphoretic, using accessory muscles
- Cardiovascular: Tachycardic, pulsus paradoxus 18 mmHg
- Pulmonary: Poor air movement, minimal wheezing (ominous sign), no rhonchi
- Extremities: No cyanosis

### Initial Workup
- **ABG (room air)**: pH 7.38, PaCO2 42 mmHg, PaO2 58 mmHg
- **Chest X-ray**: Hyperinflation, no infiltrates or pneumothorax
- **CBC**: WBC 11,000/μL with 5% eosinophils

### Clinical Image
![Severe Asthma](image_02.png)
*Figure 2: Patient in tripod position with accessory muscle use during acute severe asthma attack, demonstrating typical posture to optimize respiratory mechanics.*

**Image Source**: Educational illustration for teaching purposes.

### Questions

1. **What is concerning about this patient's PCO2 level?**
   - A) It is too low
   - B) A normal PCO2 in acute severe asthma suggests impending respiratory failure
   - C) It indicates good compensation
   - D) It is not concerning

2. **What features indicate severe/life-threatening asthma in this patient?**
   - A) Mild tachycardia only
   - B) History of ICU admission, inability to speak sentences, poor air entry, pulsus paradoxus >12 mmHg, normal PCO2
   - C) Wheezing
   - D) Eosinophilia

3. **What is the significance of "silent chest" in asthma?**
   - A) Good prognostic sign - bronchospasm is resolving
   - B) Life-threatening sign indicating severe air trapping with minimal air movement
   - C) Normal finding during treatment
   - D) Indicates pneumonia

4. **What is the appropriate management for this patient?**

5. **What adjunctive therapies may be considered in severe asthma?**

### Answers

1. **B) A normal PCO2 in acute severe asthma suggests impending respiratory failure** - In acute asthma, hyperventilation typically causes respiratory alkalosis with low PCO2. A normal or rising PCO2 indicates respiratory muscle fatigue and inability to maintain minute ventilation - a sign of impending respiratory failure.

2. **B) History of ICU admission, inability to speak sentences, poor air entry, pulsus paradoxus >12 mmHg, normal PCO2** - These are all features of severe/life-threatening asthma. Prior intubation is a strong risk factor for fatal asthma.

3. **B) Life-threatening sign indicating severe air trapping with minimal air movement** - "Silent chest" means air flow is so severely limited that wheezes cannot be generated. This is a pre-arrest finding requiring immediate aggressive management.

4. **Management of acute severe asthma**:
   - **Oxygen**: High-flow to maintain SpO2 94-98%
   - **Bronchodilators**: Continuous nebulized albuterol (or frequent SABA + SAMA)
   - **Corticosteroids**: IV methylprednisolone 125 mg or equivalent
   - **Magnesium sulfate**: 2 g IV over 20 minutes (bronchial smooth muscle relaxation)
   - **Consider**: IV terbutaline, IV aminophylline, heliox
   - **Intubation**: If respiratory failure progresses despite treatment
   - **ICU admission**: Required for this severity

5. **Adjunctive therapies in severe asthma**:
   - **IV magnesium sulfate**: 2 g IV; relaxes bronchial smooth muscle
   - **Subcutaneous/IV epinephrine**: If anaphylaxis component or no IV access
   - **IV ketamine**: Bronchodilator properties; useful for intubation
   - **Heliox**: Helium-oxygen mixture reduces airway resistance
   - **NIPPV**: May help in selected patients; requires close monitoring
   - **ECMO**: Rarely, for refractory cases with severe hypercapnia

---

## Case 3: New Diagnosis of Asthma vs. COPD

### Patient Presentation
A 55-year-old woman presents with 2 years of progressively worsening shortness of breath and cough. She has a 20-pack-year smoking history but quit 5 years ago. She notes symptoms are worse in the spring and when she exercises. She has a history of allergic rhinitis and eczema as a child.

### Vital Signs
- Blood Pressure: 128/78 mmHg
- Heart Rate: 76 bpm
- Respiratory Rate: 16/min
- Oxygen Saturation: 97% on room air

### Physical Examination
- General: Well-appearing, no distress at rest
- HEENT: Boggy nasal mucosa
- Cardiovascular: Regular rate and rhythm
- Pulmonary: Mild expiratory wheezes bilaterally, no prolonged expiration

### Pulmonary Function Tests
- **Pre-bronchodilator**: FEV1 68% predicted, FVC 85% predicted, FEV1/FVC 0.62
- **Post-bronchodilator**: FEV1 82% predicted (improvement of 14% and 280 mL)
- **DLCO**: 92% predicted (normal)

### Additional Testing
- **CBC**: WBC 8,500/μL with 8% eosinophils
- **Total IgE**: 285 IU/mL (elevated)
- **Chest X-ray**: No hyperinflation, clear lung fields

### Clinical Image
![Spirometry Flow-Volume Loop](image_03.png)
*Figure 3: Flow-volume loop demonstrating obstructive pattern with significant bronchodilator response (dashed line = post-bronchodilator), favoring asthma over COPD.*

**Image Source**: Educational illustration for teaching purposes.

### Questions

1. **What features favor asthma over COPD in this patient?**
   - A) Smoking history
   - B) Age of onset
   - C) Significant bronchodilator response (>12% and >200 mL), atopic history, peripheral eosinophilia, normal DLCO
   - D) Chronic cough

2. **What spirometry finding defines obstructive lung disease?**
   - A) FEV1 <80% predicted
   - B) FEV1/FVC ratio <0.70
   - C) FVC <80% predicted
   - D) DLCO <80% predicted

3. **What is Asthma-COPD Overlap (ACO)?**
   - A) Misdiagnosis of asthma
   - B) Patients with features of both asthma and COPD, often with significant smoking history and eosinophilic inflammation
   - C) Severe asthma only
   - D) COPD with frequent exacerbations

4. **What treatment approach would be appropriate for this patient?**

5. **How does DLCO help differentiate asthma from COPD?**

### Answers

1. **C) Significant bronchodilator response (>12% and >200 mL), atopic history, peripheral eosinophilia, normal DLCO** - These features suggest asthma: reversibility >12% and >200 mL, personal/family history of atopy (allergic rhinitis, eczema), elevated eosinophils, elevated IgE, and normal DLCO (preserved gas exchange).

2. **B) FEV1/FVC ratio <0.70** - Obstructive lung disease is defined by FEV1/FVC <0.70 (or below lower limit of normal). FEV1% predicted indicates severity once obstruction is established.

3. **B) Patients with features of both asthma and COPD, often with significant smoking history and eosinophilic inflammation** - ACO includes patients with persistent airflow limitation who have features of both conditions. They often have smoking history, late-onset symptoms, but also reversibility, eosinophilia, and atopy.

4. **Treatment approach**:
   - Given features of both asthma and possible ACO:
   - **First-line**: ICS-LABA combination (e.g., fluticasone-salmeterol or budesonide-formoterol)
   - **Add LAMA** (tiotropium) if inadequate control
   - **Avoid LABA monotherapy** - always use with ICS in asthma
   - **Rescue**: SABA PRN or ICS-formoterol as needed
   - **Allergen avoidance**: Given atopic history
   - **Consider**: Allergy testing, evaluation for biologic therapy if eosinophilic

5. **DLCO in asthma vs. COPD**:
   - **Asthma**: DLCO is typically normal because there is no parenchymal destruction
   - **COPD (emphysema)**: DLCO is reduced due to alveolar destruction and loss of gas-exchanging surface area
   - **Chronic bronchitis** (COPD without emphysema): DLCO may be preserved
   - Normal DLCO in this patient with reversible obstruction favors asthma

---

## Learning Points

1. **COPD exacerbations** are characterized by increased dyspnea, sputum volume, and sputum purulence; treatment includes bronchodilators, steroids, antibiotics if indicated, and NIPPV for respiratory acidosis.

2. **Target SpO2 of 88-92%** in COPD prevents oxygen-induced hypercapnia in chronic CO2 retainers.

3. **Severe asthma** with normal/rising PCO2, silent chest, or inability to speak indicates impending respiratory failure requiring aggressive treatment.

4. **Bronchodilator reversibility** (>12% and >200 mL) favors asthma; DLCO reduction suggests emphysema.

5. **ICS-LABA** is first-line for asthma and ACO; LABA monotherapy is contraindicated in asthma due to increased mortality risk.